During Tuesday’s Current trade, Shares of StanCorp Financial Group, Inc. (NYSE:SFG), lost -0.09% to $113.76.
The fairness of the projected acquisition of StanCorp Financial Group (“SFG” or the “Company”) by Meiji Yasuda Life Insurance Company (“Meiji Yasuda”) is the subject of an investigation by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation is focusing on possible breaches of fiduciary duty and other violations of law by the Board of Directors of SFG for agreeing to sell the Company to Meiji Yasuda. On July 23, 2015, the Company declared it had reached a definitive agreement for Meiji Yasuda to acquire SFG in a transaction valued at about $5 billion. Under the terms of the agreement, SFG shareholders will receive $115 in cash for each SFG share they own.
WeissLaw is investigating whether SFG’s Board acted to maximize shareholder value preceding to entering into the agreement. Notably, on July 23, 2015, the Company declared positive financial results. It stated net income of $64.3 million in the second quarter of 2015, as contrast to $40.8 million in the same period of the previous year, representing an enhance of about 58% year-over year.
StanCorp Financial Group, Inc., through its auxiliaries, provides financial products and services in the United States. The company operates in two segments, Insurance Services and Asset Administration. The Insurance Services segment offers group and individual disability insurance; group life, and accidental death and dismemberment insurance; group dental and group vision insurance; annuity products; retirement plan products; and absence administration services to individuals and employer groups.
Shares of Edwards Lifesciences Corp (NYSE:EW), declined -0.07% to $152.61, during its current trading session.
Edwards Lifesciences Corporation (EW), the global leader in the science of heart valves and hemodynamic monitoring, recently declared that it has agreed to acquire CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system.
CardiAQ has received a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct an early feasibility study of up to 20 patients, and also plans to initiate a CE Mark study in Europe.
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.
Sarepta Therapeutics Inc (NASDAQ:SRPT), during its Tuesday’s current trading session decreased -0.44% to $31.86.
Sarepta Therapeutics, Inc. (SRPT), a developer of innovative RNA-targeted therapeutics, recently declared Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company.
Henri Termeer is the former chairman, president and chief executive officer of Genzyme Corporation, where he served for nearly three decades until retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Mr. Termeer continues to be very active in the areas of humanitarian assistance, policy issues, and innovation in providing access to healthcare. Henri and his wife, Belinda, founded the Termeer Center for Targeted Therapies at Massachusetts General Hospital in 2012. He serves on the boards of numerous scientific and healthcare institutions. He is a Fellow of the American Academy of Arts and Sciences.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Finally, Digital Realty Trust, Inc. (NYSE:DLR), decreased -0.95%, to $64.39.
Digital Realty Trust, Inc. (DLR), a leading global provider of data center and colocation solutions, declared that it will release its financial results for the second quarter 2015 after the market closes on Thursday, July 30, 2015. The company will host a conference call to talk about these results at 5:30 p.m. EDT / 2:30 p.m. PDT on Thursday, July 30, 2015.
Digital Realty Trust, Inc., a real estate investment trust (REIT), through its controlling interest in Digital Realty Trust, L.P., engages in the ownership, acquisition, development, redevelopment, and administration of technology-related real estate. It focuses on planned ally located properties containing applications and operations critical to the day-to-day operations of technology industry tenants and corporate enterprise datacenter users, counting the information technology departments of Fortune 1000 companies, and financial services companies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
